Levosimendán Zentiva (Levosimendan)

Levosimendan sensitises cardiac troponin C to calcium, which enhances myocardial contractility without increasing intracellular calcium levels. At the same time it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation that lowers preload and afterload, thereby improving overall cardiac efficiency.

The dose of Levosimendán Zentiva is determined by the prescribing clinician based on the patient’s clinical status, weight, and response to therapy. The product is supplied as an intravenous solution that is administered under continuous medical supervision in a hospital or intensive‑care setting.

The safety of levosimendan in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and the necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility by calcium sensitisation rather than raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that some clinicians find advantageous in acute heart‑failure settings.

Levosimendán Zentiva must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

The medication is supplied as an intravenous solution and is administered by a healthcare professional through a controlled infusion. The infusion rate and duration are set by the treating physician, who monitors haemodynamic parameters throughout the treatment.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischaemia, and rare allergic reactions such as anaphylaxis. Continuous cardiac and blood‑pressure monitoring is essential during infusion to detect and manage these events promptly.

Levosimendán Zentiva should be avoided in patients with uncontrolled severe hypotension, known hypersensitivity to levosimendan or any excipients, and in those with recent acute myocardial infarction where the risk of ischaemia outweighs benefit. Clinical judgment is required for each individual case.